-
China’s Henlius Biotech Partners with Sermonix for Japan Development of Breast Cancer Drug
•
Shanghai Henlius Biotech Inc. (HKG: 2696), a prominent biopharmaceutical company based in China, has announced an expansion of its licensing agreement with Sermonix Pharmaceuticals Inc., to include additional territories in Asia for the development and commercialization of HLX78 (oral lasofoxifene). This supplementary agreement facilitates a co-development partnership between Henlius and…
